A 3D quantitative imaging biomarker in pre-treatment MRI predicts overall survival after stereotactic radiation therapy of patients with a singular brain metastasis
Abstract
Background
Brain metastases (BM) are the most frequent intracranial malignant tumor. Various prognostic factors facilitate the prediction of survival; however, few have become tools for clinical use.
Purpose
To investigate the role of three-dimensional (3D) quantitative tissue enhancement in pre-treatment cranial magnetic resonance imaging (MRI) as a radiomic biomarker for survival (OS) in patients with singular BM treated with stereotactic radiation therapy (SRT).
Material and Methods
In this retrospective study, 48 patients (27 non-small cell lung cancer and 21 melanoma) with singular BM treated with SRT, were analyzed. Contrast-enhanced MRI scans of the neurocranium were used for quantitative image analyses. Segmentation-based 3D quantification was performed to measure the enhancing tumor volume. A cut-off value of 68.61% of enhancing volume was used to stratify the cohort into two groups (≤68.61% and > 68.61%). Univariable and multivariable cox regressions were used to analyze the prognostic factors of OS and intracranial progression-free survival (iPFS).
Results
The level of enhancing tumor volume achieved statistical significance in univariable and multivariable analysis for OS (univariable: P = 0.005, hazard ratio [HR] = 0.375, 95% confidence interval [CI] = 0.168–0.744; multivariable: P = 0.006, HR = 0.376, 95% CI = 0.186–0.757). Patients with high-level enhancement (>68.61% enhancing lesion volume) survived significantly longer (4.9 vs. 10.2 months) and showed significantly longer iPFS rates (univariable: P < 0.001, HR = 0.046, 95% CI = 0.009–0.245).
Conclusions
Patients with lesions that show a higher percentage of enhancement in pre-treatment MRI demonstrated improved iPFS and OS compared to those with mainly hypo-enhancing lesions. Lesion enhancement may be a radiomic marker, useful in prognostic indices for survival prediction, in patients with singular BM.
Get full access to this article
View all access and purchase options for this article.
References
1. Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases Curr Oncol Rep 2012; 14:48–54.
2. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65:87–108.
3. Schouten LJ, Rutten J, Huveneers HA, et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002; 94:2698–2705.
4. Newman SJ, Hansen HH. Proceedings: Frequency, diagnosis, and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma. Cancer 1974; 33:492–496.
5. Flanigan JC, Jilaveanu LB, Faries M, et al. Melanoma brain metastases: is it time to reassess the bias? Curr Prob Cancer 2011; 35:200–210.
6. Fife KM, Colman MH, Stevens GN, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004; 22:1293–1300.
7. Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 2010; 77:655–661.
8. Jenkinson MD, Haylock B, Shenoy A, et al. Management of cerebral metastasis: evidence-based approach for surgery, stereotactic radiosurgery and radiotherapy. Eur J Cancer 2011; 47:649–655.
9. Nieder C. Two new prognostic indices for brain metastases–where do we go from here? Strahlenther Onkol 2008; 184:488–489.
10. Rades D, Gerdan L, Segedin B, et al. Brain metastasis. Prognostic value of the number of involved extracranial organs. Strahlenther Onkol 2013; 189:996–1000.
11. Khademalhosseini Z, Khademolhosseini M, Kummer B, et al. [Stereotactic radiosurgery for brainstem metastases: In experienced hands a good treatment option with excellent risk-benefit ratio]. Strahlenther Onkol 2017; 193:347–349.
12. Arrieta O, Villarreal-Garza C, Zamora J, et al. Long-term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole-brain radiotherapy and thoracic chemoradiation. Radiat Oncol 2011; 6:166.
13. Deutsch M, Parsons JA, Mercado R Jr. Radiotherapy for intracranial metastases. Cancer 1974; 34:1607–1611.
14. Linskey ME, Andrews DW, Asher AL, et al. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96:45–68.
15. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995; 13:8–10.
16. Kaul D, Angelidis A, Budach V, et al. Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer. Radiat Oncol 2015;10:244.
17. Golden DW, Lamborn KR, McDermott MW, et al. Prognostic factors and grading systems for overall survival in patients treated with radiosurgery for brain metastases: variation by primary site. J Neurosurg 2008; 109 Suppl:77–86.
18. Rades D, Dziggel L, Segedin B, et al. A new survival score for patients with brain metastases from non-small cell lung cancer. Strahlenther Onkol 2013; 189:777–781.
19. Weltman E, Salvajoli JV, Brandt RA, et al. Radiosurgery for brain metastases: a score index for predicting prognosis. Int J Radiat Oncol Biol Phys 2000; 46:1155–1161.
20. Davis PC, Hudgins PA, Peterman SB, et al. Diagnosis of cerebral metastases: double-dose delayed CT vs contrast-enhanced MR imaging. Am J Neuroradiol 1991; 12:293–300.
21. Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neurooncol 1999; 44:275–281.
22. Peeken JC, Nusslin F, Combs SE. “Radio-oncomics”: The potential of radiomics in radiation oncology. Strahlenther Onkol 2017; 193:767–779.
23. Schneider T, Chapiro J, Lin M, et al. 3D quantitative assessment of response to fractionated stereotactic radiotherapy and single-session stereotactic radiosurgery of vestibular schwannoma. Eur Radiol 2016;26:849–857.
24. Chapiro J, Duran R, Lin M, et al. Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver. Eur Radiol 2015;25:1993–2003.
25. Tacher V, Lin M, Chao M, et al. Semiautomatic volumetric tumor segmentation for hepatocellular carcinoma: comparison between C-arm cone beam computed tomography and MRI. Acad Radiol 2013; 20:446–452.
26. Budczies J, Klauschen F, Sinn BV, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One 2012; 7:e51862.
27. RC Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2008.
28. Chamberlain MC. Brain metastases: a medical neuro-oncology perspective. Expert Rev Neurother 2010; 10:563–573.
29. Sperduto PW, Berkey B, Gaspar LE, et al. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 2008; 70:510–514.
30. Chapiro J, Lin M, Duran R, et al. Assessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI. Expert Rev Anticancer Ther 2015;15:199–205.
31. Fleckenstein FN, Schernthaner RE, Duran R, et al. 3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival. Eur Radiol 2016; 26:3243–3252.
32. Donaldson SB, Buckley DL, O’Connor JP, et al. Enhancing fraction measured using dynamic contrast-enhanced MRI predicts disease-free survival in patients with carcinoma of the cervix. Br J Cancer 2010; 102:23–26.
33. Duran R, Chapiro J, Frangakis C, et al. Uveal Melanoma Metastatic to the Liver: The Role of Quantitative Volumetric Contrast-Enhanced MR Imaging in the Assessment of Early Tumor Response after Transarterial Chemoembolization. Transl Oncol 2014;7:447–455.
34. Tacher V, Lin M, Duran R, et al. Comparison of existing response criteria in patients with hepatocellular carcinoma treated with transarterial chemoembolization using a 3D quantitative approach. Radiology 2016; 278:275–284.
35. Chapiro J, Duran R, Lin M, et al. Transarterial chemoembolization in soft-tissue sarcoma metastases to the liver - the use of imaging biomarkers as predictors of patient survival. Eur J Radiol 2015;84:424–430.
36. Conger AD. The effect of oxygen on the radiosensitivity of mammalian cells. Radiology 1956; 66:63–69.
37. Chapiro J, Duran R, Lin M, et al. Three-Dimensional Quantitative Assessment of Uterine Fibroid Response after Uterine Artery Embolization Using Contrast-Enhanced MR Imaging. J Vasc Interv Radiol 2015;26:670–678 e672.
38. Pellerin O, Lin M, Bhagat N, et al. Comparison of semi-automatic volumetric VX2 hepatic tumor segmentation from cone beam CT and multi-detector CT with histology in rabbit models. Acad Radiol 2013; 20:115–121.
39. Chapiro J, Wood LD, Lin M, et al. Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis. Radiology 2014;273:746–758.
Cite article
Cite article
Cite article
OR
Download to reference manager
If you have citation software installed, you can download article citation data to the citation manager of your choice
Information, rights and permissions
Information
Published In
Article first published online: March 6, 2019
Issue published: November 2019
Keywords
PubMed: 30841703
Authors
Metrics and citations
Metrics
Article usage*
Total views and downloads: 270
*Article usage tracking started in December 2016
Altmetric
See the impact this article is making through the number of times it’s been read, and the Altmetric Score.
Learn more about the Altmetric Scores
Articles citing this one
Receive email alerts when this article is cited
Web of Science: 15 view articles Opens in new tab
Crossref: 16
- Radiomics of metastatic brain tumor as a predictive image biomarker of...
- A radiomics signature associated with underlying gene expression patte...
- AI Evaluation of Imaging Factors in the Evolution of Stage-Treated Met...
- Brain metastases from NSCLC treated with stereotactic radiotherapy: pr...
- Predicting Adverse Radiation Effects in Brain Tumors After Stereotacti...
- Machine Learning-Based Radiomics in Neuro-Oncology
- Radiomics outperforms semantic features for prediction of response to ...
- The role of feature-based radiomics for predicting response and radiat...
- Radiomics as an emerging tool in the management of brain metastases
- Computer Tomography Radiomics-Based Nomogram in the Survival Predictio...
- Classification of true progression after radiotherapy of brain metasta...
- Radiomics and Deep Learning in Brain Metastases: Current Trends and Ro...
- Virtual biopsy using MRI radiomics for prediction of BRAF status in me...
- Applications of radiomics and machine learning for radiotherapy of mal...
- Novel cancer therapies for advanced cutaneous melanoma: The added valu...
- PET/MRI Radiomics in Patients With Brain Metastases
Figures and tables
Figures & Media
Tables
View Options
Get access
Access options
If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:
loading institutional access options
Nordic Society of Medical Radiology members can access this journal content using society membership credentials.
Nordic Society of Medical Radiology members can access this journal content using society membership credentials.
Alternatively, view purchase options below:
Purchase 24 hour online access to view and download content.
Access journal content via a DeepDyve subscription or find out more about this option.
